Joseph Keenan

1 day ago | fiercepharma.com | Joseph Keenan

Famar, a portfolio company of the private equity firm of MidEuropa, is set to acquire a sterile manufacturing facility in Homburg, Germany, from MiP Pharma as part of the Greek CDMO’s plan to expand its European operations. The deal is slated to give Famar production capabilities for "high-value dosage forms" as well as aseptic and lyophilized fill-finish capacity, MidEuropa said in a May 13 press release. Financial details of the purchase weren’t disclosed.

2 days ago | fiercepharma.com | Joseph Keenan

Ratio Therapeutics, which specializes in the growing field of radiopharmaceuticals, hasinked a deal to build a new research and manufacturing facility in Salt Lake City, Utah. The plant, which Ratio expects to get up and running in the second half of 2027, is part of a new pact with the Medical Innovation Technology Management division of Wasatch Group, which is partnering on the facility and will chip in on its construction.

1 week ago | fiercepharma.com | Joseph Keenan

Amneal Pharmaceuticals inked a collaboration deal with syringe maker Apiject that will see the New Jersey-based biopharma boost its production capacity in the U.S. as well as support its efforts to reshore drug manufacturing in the country. As part of the collaboration, Amneal will install new manufacturing lines at Apiject’s Brookhaven, New York, facility.

1 week ago | fiercepharma.com | Joseph Keenan

Xellia Pharmaceuticals, the largest and last maker of key antibiotics APIs in Europe, will shutter its Copenhagen production facility in a move seen as a blow to EU reshoring efforts. The Danish drugmaker plans to slowly unwind operations at the facility over the next decade and move its anti-infective production “outside of Denmark,” the company said in a May 6 press release. When completed, the closure will result in the loss of about 500 jobs.

2 weeks ago | fiercepharma.com | Joseph Keenan

Samsung Biologics, which has enjoyed a booming contract drug manufacturing streak over the past year, has inked anotherdeal, this one worth 737.3 billion Korean won ($518 million). The latest production contract for the South Korean CDMO is with an undisclosed U.S. pharmaceutical company and is expected to carry on through the end of 2031, Samsung said in a financial filing.